Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Titel:
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Auteur:
Reck, Martin Ciuleanu, Tudor-Eliade Schenker, Michael Bordenave, Stephanie Cobo, Manuel Juan-Vidal, Oscar Reinmuth, Niels Richardet, Eduardo Felip, Enriqueta Menezes, Juliana Cheng, Ying Mizutani, Hideaki Zurawski, Bogdan Alexandru, Aurelia Carbone, David P. Lu, Shun John, Thomas Aoyama, Takekazu Grootendorst, Diederik J. Hu, Nan Eccles, Laura J. Paz-Ares, Luis G.